Skip to main content

Striverdi Respimat FDA Approval History

FDA Approved: Yes (First approved July 31, 2014)
Brand name: Striverdi Respimat
Generic name: olodaterol
Dosage form: Inhalation Spray
Company: Boehringer Ingelheim Pharmaceuticals Inc.
Treatment for: COPD

Striverdi Respimat (olodaterol) is a once-daily, long-acting beta-agonist (LABA) for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

Development timeline for Striverdi Respimat

DateArticle
Jul 31, 2014Approval FDA Approves Striverdi Respimat to Treat Chronic Obstructive Pulmonary Disease
Jan 30, 2013FDA Advisory Committee Recommends Approval for Boehringer Ingelheim's Olodaterol for Maintenance Treatment of COPD

See also

Striverdi Respimat (olodaterol) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer